| Able also has withdrawn seven applications awaiting FDA approval of its latest generic medicines.
Two weeks ago, Able said in a news release on its Web site that it had eliminated about 200 manufacturing and other jobs out of its 421 positions.
"Their pipeline is gone. They laid off most of their staff. They are essentially out of business," health care analyst Sharon di Stefano of brokerage firm Sky Capital LLC said Friday. "I'm surprised they're still even trading" their stock.
|
| Dana--the reason some of your doctors are refusing to give you Fioricet is because they want to help you avoid analgesic rebound headache. This is a very common and debilitating condition which arises from use of pain medications, particularly those containing butalbital, to abort headaches--the headaches start coming more frequently, requiring more frequent use of the med, until you have daily headaches that respond poorly to almost any treatment (there is treatment available, but youll need to consult a neurologist who has a real interest in headaches to really fix the problem). Many effective preventative medications are available, but no one can predetermine with certainty which particular therapy will be best for you--that takes time, and effort, and more than a little trial-and-error. Find a physician who will spend some time with you and listen to your story. |
| From: chuckfras...@yahoo.com (Chuck) coughman wrote in message ... I got 30 fioricet with codeine. i think each one has 30mg of codiene in them. I believe there is also some APAP, and some Butalbitol? A few weeks |
| Able Laboratories Inc., reeling since last month's disclosure of sloppy manufacturing and testing procedures triggered the recall of all 44 of its generic drugs, announced more layoffs while saying it expected further cuts.
On Thursday, the Cranbury-based company said it expects more job cuts and can give no assurance when it may resume manufacturing. It didn't disclose the number of cuts.
|
| "The fact that they pulled their FDA submissions is very telling," especially with the company saying its data on those drugs might be faulty, di Stefano said. She said she has never seen a company completely shut down its drug pipeline.
An Able spokeswoman who would not give her name said Friday the company is "not commenting at this time" and refused to answer any questions.
|
